Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1988 1
1989 1
1996 1
1998 3
1999 2
2000 3
2002 2
2004 1
2005 1
2006 2
2007 3
2008 3
2009 1
2010 3
2011 4
2012 1
2013 1
2014 3
2015 2
2016 4
2017 7
2018 6
2019 7
2020 5
2021 11
2022 8
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for anti de visser
Search for Yanti De Visser instead (3 results)
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.
de Visser KE, Joyce JA. de Visser KE, et al. Cancer Cell. 2023 Mar 13;41(3):374-403. doi: 10.1016/j.ccell.2023.02.016. Cancer Cell. 2023. PMID: 36917948 Free article. Review.
Understanding the complex interplay between tumor cell-intrinsic, cell-extrinsic, and systemic mediators of disease progression is critical for the rational development of effective anti-cancer treatments....
Understanding the complex interplay between tumor cell-intrinsic, cell-extrinsic, and systemic mediators of disease progression is critical …
Immunoediting instructs tumor metabolic reprogramming to support immune evasion.
Tsai CH, Chuang YM, Li X, Yu YR, Tzeng SF, Teoh ST, Lindblad KE, Di Matteo M, Cheng WC, Hsueh PC, Kao KC, Imrichova H, Duan L, Gallart-Ayala H, Hsiao PW, Mazzone M, Ivanesevic J, Liu X, de Visser KE, Lujambio A, Lunt SY, Kaech SM, Ho PC. Tsai CH, et al. Among authors: de visser ke. Cell Metab. 2023 Jan 3;35(1):118-133.e7. doi: 10.1016/j.cmet.2022.12.003. Cell Metab. 2023. PMID: 36599297 Free PMC article.
Immunoediting sculpts immunogenicity and thwarts host anti-tumor responses in tumor cells during tumorigenesis; however, it remains unknown whether metabolic programming of tumor cells can be guided by immunosurveillance. ...
Immunoediting sculpts immunogenicity and thwarts host anti-tumor responses in tumor cells during tumorigenesis; however, it remains u …
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis. ...
Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in pati …
Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review.
Kamperman RG, van der Kooi AJ, de Visser M, Aronica E, Raaphorst J. Kamperman RG, et al. Among authors: de visser m. Int J Mol Sci. 2022 Apr 13;23(8):4301. doi: 10.3390/ijms23084301. Int J Mol Sci. 2022. PMID: 35457124 Free PMC article. Review.
Established subgroups of IIM include dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), overlap myositis (OM) and inclusion body myositis (IBM). ...
Established subgroups of IIM include dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASy …
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D. Ries CH, et al. Among authors: de visser ke. Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2. Cancer Cell. 2014. PMID: 24898549 Free article.
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies.
Cavagna L, Meloni F, Meyer A, Sambataro G, Belliato M, De Langhe E, Cavazzana I, Pipitone N, Triantafyllias K, Mosca M, Barsotti S, Zampogna G, Biglia A, Emmi G, De Visser M, Van Der Kooi A, Parronchi P, Hirschi S, da Silva JAP, Scirè CA, Furini F, Giannini M, Martinez Gonzalez O, Damian L, Piette Y, Smith V, Mera-Valera A, Bachiller-Corral J, Cabezas Rodriguez I, Brandy-Garcia AM, Maurier F, Perrin J, Gonzalez-Moreno J, Drott U, Delbruck C, Schwarting A, Arrigoni E, Sebastiani GD, Iuliano A, Nannini C, Quartuccio L, Rodriguez Cambron AB, Blázquez Cañamero MÁ, Villa Blanco I, Cagnotto G, Pesci A, Luppi F, Dei G, Romero Bueno FI, Franceschini F, Chiapparoli I, Zanframundo G, Lettieri S, De Stefano L, Cutolo M, Mathieu A, Piga M, Prieto-González S, Moraes-Fontes MF, Fonseca JE, Jovani V, Riccieri V, Santaniello A, Montfort S, Bilocca D, Erre GL, Bartoloni E, Gerli R, Monti MC, Lorenz HM, Sambataro D, Bellando Randone S, Schneider U, Valenzuela C, Lopez-Mejias R, Cifrian J, Mejia M, Gonzalez Perez MI, Wendel S, Fornaro M, De Luca G, Orsolini G, Rossini M, Dieude P, Knitza J, Castañeda S, Voll RE, Rojas-Serrano J, Valentini A, Vancheri C, Matucci-Cerinic M, Feist E, Codullo V, … See abstract for full author list ➔ Cavagna L, et al. Among authors: de visser m. Clin Exp Rheumatol. 2022 Feb;40(2):274-283. doi: 10.55563/clinexprheumatol/di1083. Epub 2022 Feb 16. Clin Exp Rheumatol. 2022. PMID: 35200123 Free article.
RESULTS: 149 anti-MDA5 positive patients (median onset age 53 years, median disease duration 18 months), mainly females (100, 67%), were included. ...Anti-MDA5 antibody positivity should be considered even when baseline autoimmune screening is negative, anti- …
RESULTS: 149 anti-MDA5 positive patients (median onset age 53 years, median disease duration 18 months), mainly females (100, 67%), w …
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape.
Wellenstein MD, de Visser KE. Wellenstein MD, et al. Among authors: de visser ke. Immunity. 2018 Mar 20;48(3):399-416. doi: 10.1016/j.immuni.2018.03.004. Immunity. 2018. PMID: 29562192 Free article. Review.
Owing to their tremendous diversity and plasticity, immune cells exert multifaceted functions in tumor-bearing hosts, ranging from anti-tumor to pro-tumor activities. Tumor immune landscapes differ greatly between and within cancer types. ...
Owing to their tremendous diversity and plasticity, immune cells exert multifaceted functions in tumor-bearing hosts, ranging from anti …
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.
Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F; REGAIN Study Group. Siddiqi ZA, et al. Muscle Nerve. 2021 Dec;64(6):662-669. doi: 10.1002/mus.27422. Epub 2021 Oct 14. Muscle Nerve. 2021. PMID: 34590717 Clinical Trial.
The aim of this analysis was to evaluate the efficacy and safety of eculizumab in patients with refractory anti-acetylcholine receptor antibody-positive (AChR(+) ) gMG previously treated with rituximab. ...
The aim of this analysis was to evaluate the efficacy and safety of eculizumab in patients with refractory anti-acetylcholine recepto …
Impact of cancer cell-intrinsic features on neutrophil behavior.
Duits DEM, de Visser KE. Duits DEM, et al. Among authors: de visser ke. Semin Immunol. 2021 Oct;57:101546. doi: 10.1016/j.smim.2021.101546. Epub 2021 Dec 7. Semin Immunol. 2021. PMID: 34887163 Free article. Review.
Neutrophils are multifaceted innate immune cells that play a significant role in the progression of cancer by exerting both pro- and anti-tumorigenic functions. The crosstalk between cancer cells and neutrophils is complex and emerging evidence is pointing at cancer cell-i …
Neutrophils are multifaceted innate immune cells that play a significant role in the progression of cancer by exerting both pro- and anti …
85 results